VLTR 125xx
Alternative Names: VLTR-125xxLatest Information Update: 07 Jul 2023
At a glance
- Originator Valitor
- Class Drug conjugates; Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Dry macular degeneration
Most Recent Events
- 19 Jun 2023 Early research in Dry macular degeneration in USA (unspecified route) prior to June 2023 (Valitor pipeline, June 2023)